Russian Rusnano to invest nearly $100 million in development of innovative drugs with HSCI

13 January 2011

Russian nanotech giant Rusnano, in cooperation with Human Stem Cell Institute (HSCI) - one of Russia's leading biotechnology companies, is considering investing more than 3 billion roubles ($97.5 million) in the development of innovative pharmaceuticals based on a number of modern technologies, including the post-genomic. The new drugs are expected be positioned as a treatments for some serious, socially significant diseases.

As part of the project, the partners plan to focus on the development at least nine drugs. Three of the products will be produced on the basis of histone proteins and will be positioned for the treatment of acute leukemia and cardiovascular disease.

One of the products will be positioned for the treatment of liver cirrhosis and is expected to be based on stem cells, while five other drugs (of the BioBetters class) will be considered for the treatment of anemia, diabetes and liver disease, as well as certain pathological conditions of the immune system and growth hormone deficiency.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK